Elacridar

Elacridar is a dual inhibitor of P-glycoprotein (MRP-1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). It maximally inhibits P-glycoprotein in isolated human peripheral blood leukocytes at 200 nM. Elacridar blocks the activity of P-glycoprotein at the blood-brain barrier, altering the pharmacokinetics of certain drugs in the brain. This compound is effective against both human BCRP and the mouse homolog, Bcrp1.Formal Name: N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide. CAS Number: 143664-11-3. Synonyms: GF120918, GG918, GW0918. Molecular Formula: C34H33N3O5. Formula Weight: 563.6. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 5 mg/ml, DMF:PBS (pH 7.2)(1:3): 0.25 mg/ml, DMSO: 1 mg/ml. lambdamax: 258, 406 nm. SMILES: COC1=C(OC)C=C(CCN(CCC2=CC=C(NC(C3=CC=CC4=C3NC5=C(C=CC=C5OC)C4=O)=O)C=C2)C6)C6=C1. InChi Code: InChI=1S/C34H33N3O5/c1-40-28-9-5-7-26-32(28)36-31-25(33(26)38)6-4-8-27(31)34(39)35-24-12-10-21(11-13-24)14-16-37-17-15-22-18-29(41-2)30(42-3)19-23(22)20-37/h4-13,18-19H,14-17,20H2,1-3H3,(H,35,39)(H,36,38). InChi Key: OSFCMRGOZNQUSW-UHFFFAOYSA-N.